NASDAQ · TEM
Healthcare · Medical - Healthcare Information Services
$77.84
Down-$5.62 (-7.22%)
Updated Oct 31, 2026, 12:40 AM
SID Score
6.7/10
Composite research score
Smart Money
54/100
Neutral
Price performance · TEM
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
TEM closed at $77.84 after 20 trading sessions, up 1.58% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $75.14 | $78.40 | $75.14 | $77.84 | 4.85M |
| Oct 28, 2026 | $72.07 | $77.52 | $71.75 | $76.61 | 6.92M |
| Oct 27, 2026 | $67.18 | $72.89 | $66.50 | $72.15 | 5.09M |
| Oct 26, 2026 | $67.61 | $68.015 | $64.03 | $67.16 | 3.78M |
| Oct 23, 2026 | $63.94 | $68.145 | $62.6703 | $67.615 | 4.69M |
| Oct 22, 2026 | $66.10 | $68.29 | $61.51 | $63.81 | 6.2M |
| Oct 21, 2026 | $66.875 | $68.93 | $66.00 | $67.76 | 3.38M |
| Oct 20, 2026 | $63.80 | $69.069 | $63.20 | $66.75 | 4.99M |
| Oct 19, 2026 | $66.38 | $67.70 | $63.50 | $64.34 | 4.18M |
| Oct 16, 2026 | $70.89 | $72.4999 | $63.79 | $64.72 | 6.87M |
| Oct 15, 2026 | $64.77 | $72.805 | $63.60 | $71.13 | 6.67M |
| Oct 14, 2026 | $67.00 | $71.35 | $66.35 | $68.32 | 6.06M |
| Oct 13, 2026 | $67.12 | $68.78 | $66.17 | $68.22 | 4.16M |
| Oct 12, 2026 | $69.89 | $70.25 | $67.03 | $67.99 | 3.8M |
| Oct 9, 2026 | $70.20 | $72.96 | $69.20 | $70.93 | 6.27M |
| Oct 8, 2026 | $68.855 | $69.75 | $66.71 | $69.28 | 7.48M |
| Oct 7, 2026 | $70.10 | $73.09 | $68.6601 | $70.35 | 9.01M |
| Oct 6, 2026 | $84.965 | $87.99 | $71.34 | $71.98 | 16.56M |
| Oct 5, 2026 | $76.68 | $84.01 | $76.17 | $83.55 | 7.27M |
| Oct 2, 2026 | $77.36 | $80.305 | $75.8002 | $76.63 | 5.69M |
The latest Smart Investors Daily articles mentioning TEM.
Company
Market Activity
Research & News
TEM research
Company profile and research snapshot.
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 26, 2026 | BTIG | Buy | — |
| Oct 26, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 23, 2026 | Needham | Buy | — |
| Oct 14, 2026 | JP Morgan | Neutral | — |
| Oct 12, 2026 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 23, 2026
Key TakeawaysTempus AI shares rose 6% today after Bristol Myers Squibb agreed to license Tempus’s oncology data through 2031 and use its Lens AI platform. Bristol Myers Squibb is a returning customer committing for years, which suggests Tempus’s data is the real edge in its business.
Benzinga · Oct 23, 2026
Needham analyst Ryan MacDonald reiterates Tempus AI (NASDAQ:TEM) with a Buy and maintains $75 price target.
Yahoo · Oct 23, 2026
CHICAGO, October 23, 2026--Tempus AI, Inc. (NASDAQ: TEM, "Tempus") today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, "BMS"), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug target discovery and therapeutic development across its oncology portfolio. With this agreement, BMS significantly expands its strategic relationship with Tempus and becomes one of Tempus’s largest l
Yahoo · Oct 23, 2026
NEW YORK, October 23, 2026--Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb (NYSE: BMY, "BMS") and Tempus AI, Inc. (NASDAQ: TEM, "Tempus") to build a specialized, curated dataset and agentic AI capabilities for Alzheimer’s disease and other neurological conditions. BMS also leads Pathos’s Series E financing and gains access to Pathos Foundry across its broader R&D portfolio
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TEM.
